Who Generates More Revenue? Sarepta Therapeutics, Inc. or Merus N.V.

Biotech Revenue Battle: Sarepta vs. Merus

__timestampMerus N.V.Sarepta Therapeutics, Inc.
Wednesday, January 1, 20149448419757000
Thursday, January 1, 201514376921253000
Friday, January 1, 201628595765421000
Sunday, January 1, 201714882309154584000
Monday, January 1, 201835973461301034000
Tuesday, January 1, 201931133000380833000
Wednesday, January 1, 202029943000540099000
Friday, January 1, 202149107000701887000
Saturday, January 1, 202241586000933013000
Sunday, January 1, 2023439470001243336000
Loading chart...

Igniting the spark of knowledge

Revenue Race: Sarepta Therapeutics vs. Merus N.V.

In the dynamic world of biotechnology, revenue generation is a key indicator of a company's market position and growth potential. Over the past decade, Sarepta Therapeutics, Inc. and Merus N.V. have been at the forefront of innovation, but how do they compare in terms of revenue?

From 2014 to 2023, Sarepta Therapeutics has consistently outperformed Merus N.V. in revenue generation. In 2023, Sarepta's revenue soared to approximately $1.24 billion, marking a staggering 1,200% increase from 2014. In contrast, Merus N.V. achieved a revenue of around $44 million in 2023, reflecting a significant growth of over 4,500% since 2014, albeit from a much smaller base.

This comparison highlights the rapid growth trajectory of both companies, with Sarepta leading the charge in absolute terms, while Merus showcases impressive percentage growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025